Stockwinners Market Radar for November 19, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:03 EST Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. The CEO of Cruise, General Motors' (GM) robot taxi unit, on Saturday apologized for the company's situation following an accident that led to the pause of its self-driving vehicle operations while it conducts a safety review, Reuters' Greg Bensinger and Hyunjoo Jin report. In an email to staff reviewed by Reuters, Cruise CEO Kyle Vogt also said the firm would make a new tender offer to allow employees to sell shares, just two days after cancelling an earlier offer. 2. A venture of two nonprofits and Related Fund Management is poised to win an auction for billions of dollars of Signature Bank (SBNY) loans backed by New York apartments, The Wall Street Journal's Peter Grant reports, citing people familiar with the matter. The venture's leading bid of less than 70 cents of the loan's face value shows how much the value of New York's rent-regulated apartment sector has deteriorated in recent years. A formal winner could be awarded as early as Monday, according to a person familiar with the auction of real-estate assets once owned by the failed bank. 3. Viatris (VTRS) is the cheapest stock in the S&P 500, trading at just 3.3-times earnings, with a dividend yield of 5.1%, Jack Hough writes in this week's edition of Barron's. This year, the company is likely to generate more than 20% of its stock market value in free cash. Yet only three of 11 analysts who cover the stock recommend buying it. Think carefully before doing so, the author says. Jefferies upgraded the stock in January, predicting a 29% rise. But so far it has gotten a 20% slide, the publication notes. Viatris used to be called Mylan, widely known for buying EpiPen and then jacking up the price per two-pack from about $100 to $600 between 2007 and 2016, says Hough. 4. LionsGate's (LGF.B) "The Hunger Games: The Ballad of Songbirds and Snakes" opened to $44M, winning this weekend at the domestic box office. Overseas, the Hunger Games prequel earned an estimated $54.5M. "The Ballad of Songbirds and Snakes" sports a B+ CinemaScore, which is the lowest of the franchise. 5. First Citizens BancShares (FCNCA) saw a positive mention in this week's edition of Barron's, while Cisco (CSCO) was mentioned cautiously.

18:17 EST MediciNova announces new data, results of Phase 2 trial of MN-166 in GBM - MediciNova announced that the company's collaborator has presented new data and results of a Phase 2 clinical trial of MN-166 in glioblastoma patients at the 28th Annual Meeting of the Society for Neuro-Oncology held November 15 - 19, 2023 in Vancouver, Canada. The presentation also included data from preclinical studies which evaluated the combination of MN-166 and anti-PD1 or anti-PD-L1 therapy in GBM models. The primary endpoints of this Phase 2 clinical trial were safety and tolerability of MN-166 and temozolomide combination treatment and efficacy of the combination treatment defined as progression-free survival rate at 6 months using the RANO criteria. MN-166 and TMZ combination treatment was safe and well-tolerated, and no unexpected adverse effects were reported. The trial enrolled a total of 62 patients, including 36 newly diagnosed GBM patients and 26 recurrent GBM patients. Progression-Free Survival at 6 months was 44% for new GBM and 31% for recurrent GBM. Immunohistochemistry evaluation was performed for the patients whose pre-treatment tumor tissue samples were available from resected tumors at the initial surgery or biopsy to evaluate MIF, pERK, Ki67, CD3, CD11b, and CD74. CD3 expression was a good predictor for tumor progression at five months in recurrent glioblastoma subjects treated with MN-166 and TMZ as subjects with progression had higher CD3 tumor infiltration than subjects with no progression.